Historical Valuation
Rockwell Medical Inc (RMTI) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.48 is considered Undervalued compared with the five-year average of -0.15. The fair price of Rockwell Medical Inc (RMTI) is between 1.26 to 2.51 according to relative valuation methord. Compared to the current price of 0.95 USD , Rockwell Medical Inc is Undervalued By 24.71%.
Relative Value
Fair Zone
1.26-2.51
Current Price：0.95
24.71%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Rockwell Medical Inc (RMTI) has a current Price-to-Book (P/B) ratio of 0.92. Compared to its 3-year average P/B ratio of 2.44 , the current P/B ratio is approximately -62.38% higher. Relative to its 5-year average P/B ratio of 2.74, the current P/B ratio is about -66.44% higher. Rockwell Medical Inc (RMTI) has a Forward Free Cash Flow (FCF) yield of approximately -8.63%. Compared to its 3-year average FCF yield of -14.92%, the current FCF yield is approximately -42.16% lower. Relative to its 5-year average FCF yield of -54.51% , the current FCF yield is about -84.17% lower.
P/B
Median3y
2.44
Median5y
2.74
FCF Yield
Median3y
-14.92
Median5y
-54.51
Competitors Valuation Multiple
AI Analysis for RMTI
The average P/S ratio for RMTI competitors is 1.99, providing a benchmark for relative valuation. Rockwell Medical Inc Corp (RMTI.O) exhibits a P/S ratio of 0.48, which is -75.76% above the industry average. Given its robust revenue growth of -43.75%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for RMTI
1Y
3Y
5Y
Market capitalization of RMTI increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of RMTI in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is RMTI currently overvalued or undervalued?
Rockwell Medical Inc (RMTI) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.48 is considered Undervalued compared with the five-year average of -0.15. The fair price of Rockwell Medical Inc (RMTI) is between 1.26 to 2.51 according to relative valuation methord. Compared to the current price of 0.95 USD , Rockwell Medical Inc is Undervalued By 24.71% .
What is Rockwell Medical Inc (RMTI) fair value?
RMTI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Rockwell Medical Inc (RMTI) is between 1.26 to 2.51 according to relative valuation methord.
How does RMTI's valuation metrics compare to the industry average?
The average P/S ratio for RMTI's competitors is 1.99, providing a benchmark for relative valuation. Rockwell Medical Inc Corp (RMTI) exhibits a P/S ratio of 0.48, which is -75.76% above the industry average. Given its robust revenue growth of -43.75%, this premium appears unsustainable.
What is the current P/B ratio for Rockwell Medical Inc (RMTI) as of Jan 10 2026?
As of Jan 10 2026, Rockwell Medical Inc (RMTI) has a P/B ratio of 0.92. This indicates that the market values RMTI at 0.92 times its book value.
What is the current FCF Yield for Rockwell Medical Inc (RMTI) as of Jan 10 2026?
As of Jan 10 2026, Rockwell Medical Inc (RMTI) has a FCF Yield of -8.63%. This means that for every dollar of Rockwell Medical Inc’s market capitalization, the company generates -8.63 cents in free cash flow.
What is the current Forward P/E ratio for Rockwell Medical Inc (RMTI) as of Jan 10 2026?
As of Jan 10 2026, Rockwell Medical Inc (RMTI) has a Forward P/E ratio of -6.91. This means the market is willing to pay $-6.91 for every dollar of Rockwell Medical Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Rockwell Medical Inc (RMTI) as of Jan 10 2026?
As of Jan 10 2026, Rockwell Medical Inc (RMTI) has a Forward P/S ratio of 0.48. This means the market is valuing RMTI at $0.48 for every dollar of expected revenue over the next 12 months.